PARTICIPATION IN CANCER AND LEUKEMIA GROUP B

参与癌症和白血病 B 组

• 批准号: 3556557
• 负责人: DAVID B DUGGAN
• 金额: $ 19.34万
• 依托单位: UPSTATE MEDICAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556557
• 关键词: Retroviridae; acute leukemia; anthracyclines; biological response modifiers; biopsy; bone marrow transplantation; breast neoplasms; cancer information system; cancer rehabilitation mental health service; clinical trials; clone cells; combination cancer therapy; cooperative study; cytogenetics; cytosine arabinoside; diagnosis design /evaluation; drug adverse effect; drug design /synthesis /production; drug metabolism; human subject; human therapy evaluation; interferons; lymphoma; medical education; medical outreach /case finding; monoclonal antibody; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; pediatric neoplasm /cancer; radioimmunoassay; tumor necrosis factor alpha

This proposal requests continuation funding for institutional participation of the SUNY Health Science Center (Upstate Medical Center) Syracuse, New York, in the clinical research activities of Cancer and Leukemia Group B (CALGB). CALGB is a multi-institutional cooperative reserach group dedicated to the systematic planning, initiation, conduct analysis, and reporting of research as applied to therapy of patients with malignant disease. The scope of interest of CALGB and our institutional participation includes a wide variety of malignant disorders. The current CALGB proposal involves an increase in laboratory-based evaluations as well. The program in oncology at our institution in conjunction with CALGB is truly interdisciplinary, involving the active participation of Surgery, Radiotherapy, Clinical Pathology, Psychiatry, Pathology, Cytogenetics and Internal Medicine (Hematology and Medical Oncology). The Upstate Medical Center actively participates in all phases of the CALGB program. Our personnel contribute heavily to, and are prominent in, group scientific and administrative leadership, new study design and chairmanship, development and execution of pilot studies, the testing of new chemotherapeutic agents in phase I and phase II trials in addition to the accrual of greater than 150 patient entries/year to group protocols. The Leukemia Reference Laboratory for the entire group and the Committee Chairmanship in Lymphoma are located at our institution. As a result of the funding provided by this proposal and our institutional commitment, the accrual rate for patients entered into controlled, evaluable, experimental cancer therapy will be maintained at the current high level. The broadening and deepening of the clinical research program at our institution will similarly be reflected in the depth and breadth of our scientific and administrative involvement in CALGB activities. Since our institutional participation with CALGB is the core of the interdisciplinary cancer program at our institution, additional salutary effects will continue to be evident in the education of medical students, house officers, nursing staff as well as in the continuing education of physicians in mid-New York State. In addition, the collaboration with CALGB will help translate the most recent advances in medical care and expertise to a large and diversified patient population.

该提案要求继续为机构 纽约州立大学健康科学中心（上州） 医学中心）锡拉丘兹，纽约，在临床研究 癌症和白血病组B（CALGB）的活性。 CALGB是 一个多机构合作研究小组， 系统规划、启动、进行分析和报告 应用于恶性疾病患者治疗的研究。 CALGB的利益范围和我们的机构 参与包括多种恶性疾病。 的 目前的CALGB提案涉及增加基于实验室的 评价也是。 我们机构的肿瘤学项目 与CALGB的结合是真正的跨学科，涉及 外科、放射治疗、临床病理学的积极参与， 精神病学、病理学、细胞遗传学和内科学 （血液学和医学肿瘤学）。 上州医疗中心 积极参与CALGB计划的各个阶段。 我们 人员对集团贡献很大， 科学和行政领导，新的研究设计和 主持、制定和执行试点研究， 在I期和II期试验新的化疗药物 除了超过150例患者的入组之外的试验 年，以集团为单位。 白血病参考 整个小组和委员会主席的实验室 在淋巴瘤位于我们的机构。 的结果 这一建议和我们的机构提供的资金 承诺，参与的患者的增加率 可控制的、可评估的、实验性的癌症治疗将是 保持目前的高水平。 扩大和 我们机构的临床研究项目的深化将 同样也反映在我们科学研究的深度和广度上。 并参与CALGB活动的行政工作。 由于我们 与CALGB的机构参与是核心 我们机构的跨学科癌症项目，另外 在教育方面，有益的影响将继续明显。 医学院学生，内务人员，护理人员以及在 继续教育的医生在纽约州中部约克。 在 此外，与CALGB的合作将有助于翻译 医疗保健和专业知识的最新进展， 多样化的患者群体。